Keyphrases
Progressive multiple Sclerosis
100%
Randomized Placebo-controlled Trial
100%
High Dose
100%
Erythropoietin
100%
Phase II Trial
100%
Clinical Progression
16%
Patient-completed
16%
Expanded Disability Status Scale
16%
Hand Dexterity
16%
Magnetic Resonance Imaging
16%
Placebo
16%
Single Center
16%
Intention-to-treat Principle
16%
RhEPO
16%
Placebo-controlled
16%
Treatment Effect
16%
Neuroprotective
16%
Effective Treatment
16%
Pathophysiological Mechanisms
16%
Randomized Double-blind
16%
Placebo Groups
16%
Medicine and Dentistry
Drug Megadose
100%
Multiple Sclerosis
100%
Placebo
100%
Erythropoietin
100%
Magnetic Resonance Imaging
16%
Expanded Disability Status Scale
16%
Treatment Effect
16%
Recombinant Erythropoietin
16%
Intention-to-Treat Analysis
16%
Thromboembolism
16%
Neuroprotective Agent
16%
Phlebotomy
16%
Neuroscience
Placebo
100%
Multiple Sclerosis
100%
Erythropoietin
100%
Darbepoetin Alfa
20%
Magnetic Resonance Imaging
20%
Primary Progressive Multiple Sclerosis
20%
Expanded Disability Status Scale
20%
Neuroprotective Agent
20%
Secondary Progressive Multiple Sclerosis
20%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Erythropoietin
100%
Multiple Sclerosis
100%
Thromboembolism
16%
Recombinant Erythropoietin
16%
Neuroprotective Agent
16%
Expanded Disability Status Scale
16%
Biochemistry, Genetics and Molecular Biology
Erythropoietin
100%
Drug Megadose
100%
Magnetic Resonance Imaging
20%
Phlebotomy
20%
Darbepoetin Alfa
20%